AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18039205 — intervention group
Group type: COMPARATOR
Intervention: Custom MAP group (mean arterial pressure target determined by patients' pre-bypass MAP)
Number of subjects: 412
Study 16244842 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% isoflurane with 2 mg/kg succinylcholine
Number of subjects: 20
Study 16244842 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% isoflurane with 2 mg/kg succinylcholine
Number of subjects: 20
Study 12081985 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 243
Study 12081985 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 243
Study 12081985 — intervention group
Group type: COMPARATOR
Intervention: No resolution
Number of subjects: 243
Study 9472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mgI/ml
Number of subjects: 72
Study 9472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI/ml
Number of subjects: 72
Study 9472058 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mgI/ml
Number of subjects: 72
Study 7896157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 60
Study 7896157 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 60
Study 2468975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 6 h for up to 14 days)
Number of subjects: 576
Study 2468975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 2468975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 576
Study 935972 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (histamine H2-receptor antagonist)
Number of subjects: 0
Study 935972 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline (anticholinergic)
Number of subjects: 0
Study 935972 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metiamide and Propantheline
Number of subjects: 0
Study 6987023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg
Number of subjects: 11
Study 6987023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29339109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter gourd (2.5g powder daily)
Number of subjects: 52
Study 29339109 — intervention group
Group type: COMPARATOR
Intervention: Cucumber juice (placebo)
Number of subjects: 52
Study 26651352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral conjoint therapy for PTSD (CBCT for PTSD)
Number of subjects: 40
Study 26651352 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40
Study 24684245 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone (thyroxine, T4) supplementation at doses of 4, 8, and 16 μg/(kg · day), bolus or continuous administration
Number of subjects: 166
Study 24684245 — intervention group
Group type: COMPARATOR
Intervention: Iodine only
Number of subjects: 166
Study 24684245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 22820713 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous minimal internal fixation using one or more lag screws and Ilizarov external fixation
Number of subjects: 324
Study 19945906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar posteroanterior mobilisations at 2 Hz
Number of subjects: 30
Study 19945906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar posteroanterior mobilisations at 1 Hz
Number of subjects: 30
Study 19945906 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-static lumbar posteroanterior mobilisations
Number of subjects: 30
Study 17650168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 40
Study 17650168 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 40
Study 15848674 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus+daclizumab+MMF (study arm)
Number of subjects: 39
Study 15848674 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus+steroids+MMF (control arm)
Number of subjects: 39
Study 14700085 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbitol/carbamide gum
Number of subjects: 602
Study 14700085 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbitol gum
Number of subjects: 602
Study 14700085 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol gum
Number of subjects: 602
Study 14700085 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo gum
Number of subjects: 602
Study 14700085 — intervention group
Group type: EXPERIMENTAL
Intervention: no gum
Number of subjects: 602
Study 9539412 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 47
Study 9539412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7891046 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated K85 (n = 28)
Number of subjects: 57
Study 7891046 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (n = 29)
Number of subjects: 57
Study 1978468 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (mean daily dose: 363 mg)
Number of subjects: 71
Study 1978468 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean daily dose: 9 mg)
Number of subjects: 71
Study 608798 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (attended two screening sessions)
Number of subjects: 7229
Study 608798 — intervention group
Group type: COMPARATOR
Intervention: Control group (received conventional medical care)
Number of subjects: 7229
Study 608798 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 7229
Study 608798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7229
Study 29799075 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent tacks (Protack™)
Number of subjects: 75
Study 29799075 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable tacks (Securestrap™)
Number of subjects: 75
Study 29799075 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic glue (Glubran™)
Number of subjects: 75
Study 27028771 — intervention group
Group type: EXPERIMENTAL
Intervention: AC + PI (Adductor Canal block with Periarticular Infiltration)
Number of subjects: 151
Study 27028771 — intervention group
Group type: COMPARATOR
Intervention: AC (Adductor Canal block only)
Number of subjects: 151
Study 27028771 — intervention group
Group type: COMPARATOR
Intervention: PI (Periarticular Infiltration only)
Number of subjects: 151
Study 24852500 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression (defined as >5 cumulative minutes of EEG suppression)
Number of subjects: 2662
Study 24852500 — intervention group
Group type: COMPARATOR
Intervention: Non-suppressed cohort (≤5 min suppression)
Number of subjects: 2662
Study 24852500 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression with MAP <55 mm Hg
Number of subjects: 2662
Study 24852500 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression overall
Number of subjects: 2662
Study 24852500 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression after matching and multivariable adjustment
Number of subjects: 2662
Study 22536918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 120
Study 22536918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 19900349 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg)
Number of subjects: 26
Study 19900349 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2-40 mg)
Number of subjects: 26
Study 19900349 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 19900349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SZ
Number of subjects: 26
Study 18253955 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) at a dose of 250 mg three times daily during irinotecan administration
Number of subjects: 22
Study 18253955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activated charcoal)
Number of subjects: 22
Study 16176339 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12839320 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire (CHQ‐PF28) administered at 14 days after ED visit
Number of subjects: 732
Study 12839320 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CHQ score obtained at the visit
Number of subjects: 732
Study 10919300 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine intraarticularly
Number of subjects: 40
Study 10919300 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine intraarticularly
Number of subjects: 40
Study 10919300 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg saline intraarticularly and morphine intravenously
Number of subjects: 40
Study 10919300 — intervention group
Group type: COMPARATOR
Intervention: Saline both intraarticularly and intravenously
Number of subjects: 40
Study 9014628 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography using the lateral spot (LS) electrode array and Sramek-Bernstein equation
Number of subjects: 37
Study 9014628 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography using the modified semi-circular (MSC) electrode array and Kubicek's equation
Number of subjects: 37
Study 9014628 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (SVTD)
Number of subjects: 37
Study 1488460 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family treatment
Number of subjects: 0
Study 1488460 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive family treatment
Number of subjects: 0
Study 1488460 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2951818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide + fenoterol (1 puff per 10 kg body weight, max 4 puffs; each puff contains 0.02 mg ipratropium bromide and 0.05 mg fenoterol)
Number of subjects: 30
Study 2951818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2951818 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 30
Study 29474803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET: n = 13)
Number of subjects: 48
Study 29474803 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (TAU: n = 12)
Number of subjects: 48
Study 29474803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training associated with taurine (CET+TAU: n = 11)
Number of subjects: 48
Study 29474803 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n = 12)
Number of subjects: 48
Study 27753676 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-track technique for intramuscular injection
Number of subjects: 60
Study 27753676 — intervention group
Group type: COMPARATOR
Intervention: Standard technique of intramuscular injection
Number of subjects: 60
Study 25002101 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian-Wei-Qu-Tong Pills (JWQTP) high-dose group
Number of subjects: 240
Study 25002101 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian-Wei-Qu-Tong Pills (JWQTP) low-dose group
Number of subjects: 240
Study 25002101 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 240
Study 22575316 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 1613
Study 22575316 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 1613
Study 21094364 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle functional electrical stimulation (FES) for 6 weeks
Number of subjects: 0
Study 21094364 — intervention group
Group type: COMPARATOR
Intervention: Conventional bicycle training for 6 weeks
Number of subjects: 0
Study 21094364 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FES and bicycle training
Number of subjects: 0
Study 21094364 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention FMD values
Number of subjects: 0
Study 18503515 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery plus guided tissue regeneration (e-PTFE membrane)
Number of subjects: 30
Study 18503515 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery alone (control group)
Number of subjects: 30
Study 15902961 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized anti-IL-6R monoclonal antibody (MRA), administered every 2 weeks for 12 weeks
Number of subjects: 100
Study 15902961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15902961 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MRA infusion
Number of subjects: 100
Study 12544160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial neuropsychological assessment before and after competition
Number of subjects: 18
Study 10390003 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt sheet provided before the consultation
Number of subjects: 60
Study 10390003 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching in question-asking behaviour
Number of subjects: 60
Study 10390003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 8910759 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIFN‐beta 1a (6 MIU) i.v.
Number of subjects: 12
Study 8910759 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIFN‐beta 1a (6 MIU) i.m.
Number of subjects: 12
Study 8910759 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIFN‐beta 1a (6 MIU) s.c.
Number of subjects: 12
Study 8910759 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 12
Study 1799900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 82
Study 1799900 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-reactive subjects)
Number of subjects: 82
Study 6407315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 0
Study 6407315 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 0
Study 31926856 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 3442
Study 31926856 — intervention group
Group type: COMPARATOR
Intervention: Phenogroup 1
Number of subjects: 3442
Study 31926856 — intervention group
Group type: COMPARATOR
Intervention: Phenogroup 2
Number of subjects: 3442
Study 31926856 — intervention group
Group type: COMPARATOR
Intervention: Phenogroup 3
Number of subjects: 3442
Study 31039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol-intradermal vaccination (Group 1)
Number of subjects: 36
Study 31039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal-aerosol vaccination (Group 2)
Number of subjects: 36
Study 31039172 — intervention group
Group type: COMPARATOR
Intervention: Intradermal-intradermal vaccination (Group 3)
Number of subjects: 36
Study 28820017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective social support
Number of subjects: 957
Study 28820017 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive social support
Number of subjects: 957
Study 28586612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 220
Study 28586612 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 220
Study 24627355 — intervention group
Group type: COMPARATOR
Intervention: Exercise-induced blood flow through IPAVA in older individuals
Number of subjects: 30
Study 24627355 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia-induced blood flow through IPAVA in older individuals
Number of subjects: 30
Study 24627355 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary arterial systolic pressure during exercise in older individuals
Number of subjects: 30
Study 24627355 — intervention group
Group type: COMPARATOR
Intervention: Total pulmonary resistance (TPR) during exercise in older individuals
Number of subjects: 30
Study 24627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow through IPAVA
Number of subjects: 30
Study 22990273 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight loss program (n = 30) including regular consultations with a dietitian and physician, and the use of very low‐calorie diets as necessary
Number of subjects: 60
Study 22990273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (laparoscopic adjustable gastric banding; n = 30)
Number of subjects: 60
Study 21121496 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet with neck and mandible guards
Number of subjects: 10
Study 21121496 — intervention group
Group type: COMPARATOR
Intervention: Helmet alone
Number of subjects: 10
Study 21121496 — intervention group
Group type: COMPARATOR
Intervention: Bare head
Number of subjects: 10
Study 17066402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian evaluation of group sequential clinical trial designs
Number of subjects: 0
Study 15598601 — intervention group
Group type: EXPERIMENTAL
Intervention: BWLP+GI education
Number of subjects: 53
Study 15598601 — intervention group
Group type: COMPARATOR
Intervention: BWLP
Number of subjects: 53
Study 11865371 — intervention group
Group type: EXPERIMENTAL
Intervention: Longmire's reconstruction with a pouch
Number of subjects: 41
Study 11865371 — intervention group
Group type: COMPARATOR
Intervention: Longmire's reconstruction alone
Number of subjects: 41
Study 10221742 — intervention group
Group type: EXPERIMENTAL
Intervention: SAS-SMI (Social Adjustment Scale for the Severely Mentally Ill)
Number of subjects: 670
Study 10221742 — intervention group
Group type: EXPERIMENTAL
Intervention: SAS-SMI
Number of subjects: 670
Study 8550254 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of artificially 13C‐labelled glucose dissolved in 400 ml of water
Number of subjects: 6
Study 1535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty (ELA)
Number of subjects: 96
Study 1535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser angioplasty (DLA)
Number of subjects: 96
Study 1535716 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 96
Study 6607784 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 80
Study 6607784 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 80
Study 31231828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib consolidation (1.6 mg/m2 IV on days 1, 8, 15, 22)
Number of subjects: 357
Study 31231828 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 357
Study 28489542 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping PSO with Personal‐Best‐Position Guidance (GPSO‐PG)
Number of subjects: 0
Study 28489542 — intervention group
Group type: COMPARATOR
Intervention: Current peer algorithms
Number of subjects: 0
Study 26729193 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic retrograde cholangiography (ERC) with sphincterotomy
Number of subjects: 232
Study 26729193 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 232
Study 24666552 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-antioxidant supplementation
Number of subjects: 215
Study 24666552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 22585352 — intervention group
Group type: EXPERIMENTAL
Intervention: One-screw fixation
Number of subjects: 14
Study 22585352 — intervention group
Group type: COMPARATOR
Intervention: Two-screw fixation
Number of subjects: 14
Study 19793150 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-strengthening moisturizing cream as maintenance therapy
Number of subjects: 0
Study 19793150 — intervention group
Group type: COMPARATOR
Intervention: No treatment after initial steroid course
Number of subjects: 0
Study 17510596 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Injury Partners CD‐ROM
Number of subjects: 31
Study 17510596 — intervention group
Group type: COMPARATOR
Intervention: Alternate CD‐ROM
Number of subjects: 31
Study 16145305 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate, 10 mg/day
Number of subjects: 100
Study 16145305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate, 5 mg/day
Number of subjects: 100
Study 16145305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone, 10 mg/day
Number of subjects: 100
Study 16145305 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone, 200 mg/day
Number of subjects: 100
Study 16145305 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 12133139 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Care (AC)
Number of subjects: 200
Study 12133139 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Care (PC)
Number of subjects: 200
Study 12133139 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 200
Study 9486936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril alone (monotherapy)
Number of subjects: 466
Study 9486936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril with trichlormethiazide (combination therapy)
Number of subjects: 466
Study 7965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 87
Study 7965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 87
Study 7965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 87
Study 7965272 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 87
Study 3315173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine immunotherapy
Number of subjects: 133
Study 3315173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with FAC chemotherapy
Number of subjects: 133
Study 3315173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy consolidation
Number of subjects: 133
Study 3315173 — intervention group
Group type: COMPARATOR
Intervention: FAC chemotherapy
Number of subjects: 133
Study 28610482 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles intervention delivered over approximately 9 months
Number of subjects: 235
Study 28610482 — intervention group
Group type: COMPARATOR
Intervention: Telephone-delivered intervention (control)
Number of subjects: 235